Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1Gynecologic 1

Conditions

Vomiting 2Uterine Cervical Neoplasms 1Prevention of Nausea and Vomiting Caused by Highly Emetogenic Chemotherapy 1Neoplasms 1Nausea 1Nasopharyngeal Neoplasms 1Multiple Myeloma 1Gynecologic Cancer 1Genital Neoplasms, Female 1

Interventions

Gemcitabine 11Cisplatin 11Radiotherapy, Intensity-Modulated 6tislelizumab 2nimotuzumab 2camrelizumab 2Fluorouracil 2Carboplatin 2spartalizumab 1sintilimab 1sargramostim 1pembrolizumab 1fosaprepitant 1etoposide phosphate 1Tropisetron 1Radiotherapy 1Induction Chemotherapy 1Ifosfamide 1Etoposide 1Docetaxel 1Dexamethasone 1Chemotherapy, Adjuvant 1Chemoradiotherapy 1Capecitabine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Nasopharyngeal Neoplasms × fosaprepitant × Clear all
NCT05564286 2024-02-06

Triple Antiemetic Regimen for Chemoradiotherapy in Cervical Cancer or Nasopharyngeal Cancer

Shantou University Medical College

Phase 3 Completed
116 enrolled
GynecologicHead & Neck

Uterine Cervical Neoplasms, Nasopharyngeal Neoplasms, Vomiting

Data powered by HemOnc (CC BY 4.0) Colophon âš¡